catalytic antibody


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

Catalytic antibody

An antibody that can cause useful chemical reactions. Catalytic antibodies are produced through immunization with a hapten molecule that is usually designed to resemble the transition state or intermediate of a desired reaction.

Antibodies are the recognition arm of the immune system. They are elicited, for example, when an animal is infected with a bacterium or virus. The animal produces antibodies with binding sites that are exactly complementary to some molecular feature of the invader. The antibodies can thus recognize and bind only to the invader, identifying it as foreign and leading to its destruction by the rest of the immune system. Antibodies are also elicited in large quantity when an animal is injected with molecules, a process known as immunization. A small molecule used for immunization is called a hapten. Ordinarily, only large molecules effectively elicit antibodies via immunization, so small-molecule haptens must be attached to a large protein molecule, called a carrier protein, prior to the actual immunization. Antibodies that are produced after immunization with the hapten-carrier protein conjugate are complementary to, and thus specifically bind, the hapten. See Antibody, Antigen-antibody reaction, Immunity

Ordinarily, antibody molecules simply bind; they do not catalyze reactions. However, catalytic antibodies are produced when animals are immunized with hapten molecules that are specially designed to elicit antibodies that have binding pockets capable of catalyzing chemical reactions. For example, in the simplest cases, binding forces within the antibody binding pocket are enlisted to stabilize transition states and intermediates, thereby lowering a reaction's energy barrier and increasing its rate. This can occur when the antibodies have a binding site that is complementary to a transition state or intermediate structure in terms of both three-dimensional geometry and charge distribution. This complementarity leads to catalysis by encouraging the substrate to adopt a transition-state-like geometry and charge distribution. Not only is the energy barrier lowered for the desired reaction, but other geometries and charge distributions that would lead to unwanted products can be prevented, increasing reaction selectivity.

Making antibodies with binding pockets complementary to transition states is complicated by the fact that true transition states and most reaction intermediates are unstable. Thus, true transition states or intermediates cannot be isolated or used as haptens for immunization. Instead, so-called transition-state analog molecules are used. Transition-state analog molecules are stable molecules that simply resemble a transition state (or intermediate) for a reaction of interest in terms of geometry and charge distribution. To the extent that the transition-state analog molecule resembles a true reaction transition state or intermediate, the elicited antibodies will also be complementary to that transition state or intermediate and thus lead to the catalytic acceleration of that reaction.

Catalytic antibodies bind very tightly to the transition-state analog haptens that were used to produce them during the immunization process. The transition-state analog haptens only bind and do not react with catalytic antibodies. It is the substrates, for example, the analogous ester molecules, that react. For this reason, transition-state analog haptens can interfere with the catalytic reaction by binding in the antibody binding pocket, thereby preventing any substrate molecules from binding and reacting. This inhibition by the transition-state analog hapten is always observed with catalytic antibodies, and is used as a first level of proof that catalytic antibodies are responsible for any observed catalytic reaction.

The important feature of catalysis by antibodies is that, unlike enzymes, a desired reaction selectivity can be programmed into the antibody by using an appropriately designed hapten. Catalytic antibodies almost always demonstrate a high degree of substrate selectivity. In addition, catalytic antibodies have been produced that have regioselectivity sufficient to produce a single product for a reaction in which other products are normally observed in the absence of the antibody. Finally, catalytic antibodies have been produced by immunization with a single-handed version (only left- or only right-handed) of a hapten, and only substrates with the same handedness can act as substrates for the resulting catalytic antibodies. The net result is that a high degree of stereoselectivity is observed in the antibody-catalyzed reaction.

catalytic antibody

[¦kad·ə‚lid·ik ′an·ti‚bäd·ē]
(immunology)
A large protein that is naturally produced by the immune system and has the capability of catalyzing a chemical reaction similarly to enzymes. Also known as abzyme.
Mentioned in ?
References in periodicals archive ?
Wondering if the catalytic antibody was somehow unique, they gathered natural antibodies from laboratories throughout their institute.
The company is also developing microalgae-based products for the biopesticide markets and, through an exclusive license agreement with The Scripps Research Institute, a patented aldolase catalytic antibody with potential applications in industrial synthesis for the manufacture of pharmaceuticals, fine chemicals and agricultural products.
He saw a way to put together one of these integrin-targeting drugs with a catalytic antibody.
Prolifaron's catalytic antibody technology can localize the delivery of a cytotoxic drug to a specific cell or cancer type.
We acquired rights to a new catalytic antibody that we think could eventually have potential in the treatment of cocaine overdose and addiction.
Now Landry and others at the Columbia University College of Physicians and Surgeons in New York City have created a unique catalytic antibody -- a kind of fast-acting, artificial enzyme - that may someday help humans beat cocaine addiction.
which was granted a license by BioCurex to commercialize therapeutic anti-RECAF antibodies modified according to Protokinetix's Super-Antibody proprietary technology and the Perigene (Compiegne, France) catalytic antibody technology.